Rasalet 0.5

Indications

Rasalet tablet serves as both standalone therapy and supplementary treatment for Parkinson’s disease (PD).

Pharmacology

Rasagiline, an irreversible monoamine oxidase inhibitor, acts as monotherapy in early PD or adjunct therapy in advanced cases. Its mechanism involves MAO-B inhibition, leading to increased dopamine levels in the striatum. This elevation in dopamine and subsequent enhancement of dopaminergic activity contribute to the observed therapeutic benefits in models of dopaminergic motor dysfunction.

Dosage & Administration

For monotherapy or adjunct therapy (in patients not using levodopa), the recommended dose is 1 mg orally once daily. In levodopa users, the initial dose is 0.5 mg once daily, with a potential increase to 1 mg once daily based on tolerability and clinical response. When combined with levodopa, adjusting the levodopa dose may be considered based on individual response. It’s crucial not to exceed the recommended dose due to the risk of hypertension.

Pediatric Use: Safety and efficacy in pediatric patients haven’t been established.

Geriatric Use: The safety profile in geriatric patients is comparable to non-geriatric patients.

Contraindications

Rasagiline should not be used with meperidine, tramadol, methadone, propoxyphene, or other MAO inhibitors due to the risk of serotonin syndrome.

Side Effects

Possible side effects encompass joint pain, mild headache, mood changes, dizziness, hair loss, skin rash, numbness, dry mouth, gastrointestinal disturbances, and weight changes.

Pregnancy & Lactation

Rasagiline falls under pregnancy category C. Caution is advised when prescribing to pregnant or breastfeeding women due to potential effects on prolactin secretion and unknown excretion in human milk.

Precautions & Warnings

Caution is warranted for hypertension exacerbation during Rasalet treatment. While dietary tyramine restriction isn’t mandatory, certain foods high in tyramine should be avoided. Serotonin syndrome risk increases with concomitant antidepressant and MAOI use. Adjustments are needed for patients taking ciprofloxacin or other CYP1A2 inhibitors. Special consideration is required for hepatic impairment and specific drug combinations.

Overdose Effects

Symptoms of Rasalet overdose may include CNS effects, cardiovascular manifestations, and hyperpyrexia. Supportive care and monitoring are essential, with attention to fluid and electrolyte balance and close observation for hypertensive reactions.

Therapeutic Class

Rasalet belongs to the class of antiparkinson drugs.

Storage Conditions

Store below 30ºC in a dry, light-protected area, out of children’s reach. Dispense only with a registered physician’s prescription.